Toronto Stock Exchange Symbol: AKL
MONTREAL, Aug. 27 /CNW Telbec/ - AKELA Pharma Inc., (TSX: AKL), a drug
development company focused on developing therapies for the inhalation, pain
and CNS markets, today announced that it has enrolled the first patient in the
CGRP Phase IIb clinical trial.
CGRP Phase IIb is a multi-centered, double-blind, placebo controlled,
randomized cross-over study to evaluate the effects of inhaled CGRP on
clinical and inflammatory parameters in adult patients with mild asthma
following allergen challenge test. A total of 16 patients will be enrolled in
two randomized one week treatment periods (either 5mg CGRP b.i.d. or placebo).
"Having already successfully demonstrated the CGRP bronchoprotective
efficacy for the first time in human asthmatics in the previous Phase IIa
study and based on the compelling results previously obtained in pre-clinical
studies, we are now looking forward to demonstrating its anti-inflammatory
properties. Positive results from this study would confirm CGRP's potential as
a strong alternative to the usual combination asthma therapies." said Dr.
Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.
About Akela CGRP
Akela CGRP is a 37 amino acid natural neuropeptide produced in the lung
in response to allergic stimuli. As a potential drug, it has demonstrated in
preclinical studies a profile that could make it an ideal anti-asthmatic drug
candidate with bronchodilatory, bronchoprotecting and anti-inflammatory
About Akela Pharma Inc.
Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation, pain and
CNS markets. Its lead product, for the treatment of breakthrough cancer pain,
is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R)
dry powder inhaler platform. Its pipeline also includes therapeutics for
asthma, COPD, growth hormone deficiencies and abuse deterrent formulations for
Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 82.3 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of AKELA Pharma Inc. with
respect to its performance, business and future events. Such statements
are subject to a number of risks, uncertainties and assumptions. Actual
results and events may vary significantly.
For further information:
For further information: Frédéric Dumais, Vice-President, Investor
Relations, (514) 315-3330, ext. 106, Fax: (514) 315-3325; Tina Posterli (U.S.
Media,), (917) 322-2565, email@example.com; www.akelapharma.com